Supernus Pharmaceuticals Inc
NASDAQ:SUPN

Watchlist Manager
Supernus Pharmaceuticals Inc Logo
Supernus Pharmaceuticals Inc
NASDAQ:SUPN
Watchlist
Price: 46.01 USD -2.44% Market Closed
Market Cap: 2.6B USD

Relative Value

The Relative Value of one SUPN stock under the Base Case scenario is 61.79 USD. Compared to the current market price of 46.01 USD, Supernus Pharmaceuticals Inc is Undervalued by 26%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

SUPN Relative Value
Base Case
61.79 USD
Undervaluation 26%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
3
vs Industry
41
Median 3Y
2.8
Median 5Y
2.8
Industry
2.6
Forward
3.7
vs History
vs Industry
19
Median 3Y
34.5
Median 5Y
29.1
Industry
21.7
Forward
16.5
vs History
3
vs Industry
36
Median 3Y
13.7
Median 5Y
13.3
Industry
16.6
vs History
3
vs Industry
29
Median 3Y
10.3
Median 5Y
10.4
Industry
22.5
vs History
3
vs Industry
42
Median 3Y
1.9
Median 5Y
1.9
Industry
2.3
vs History
3
vs Industry
49
Median 3Y
2.4
Median 5Y
2.6
Industry
2.9
Forward
3.3
vs History
3
vs Industry
66
Median 3Y
2.8
Median 5Y
2.9
Industry
5.5
vs History
9
vs Industry
37
Median 3Y
14.2
Median 5Y
11.5
Industry
13.1
Forward
18.4
vs History
19
vs Industry
28
Median 3Y
43.5
Median 5Y
24.2
Industry
16.6
Forward
16.9
vs History
3
vs Industry
43
Median 3Y
12.7
Median 5Y
12.7
Industry
15.8
vs History
3
vs Industry
34
Median 3Y
12.7
Median 5Y
12.8
Industry
19.1
vs History
3
vs Industry
43
Median 3Y
1.5
Median 5Y
1.4
Industry
1.9

Multiples Across Competitors

SUPN Competitors Multiples
Supernus Pharmaceuticals Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Supernus Pharmaceuticals Inc
NASDAQ:SUPN
2.7B USD 3.9 -140 18.9 57.9
US
Eli Lilly and Co
NYSE:LLY
939.9B USD 15.8 51 34.3 36.8
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
485.5B USD 5.3 19.3 15.8 20.5
CH
Roche Holding AG
SIX:ROG
252.8B CHF 4.1 26.8 11.5 13.4
UK
AstraZeneca PLC
LSE:AZN
210.6B GBP 4.8 29.9 108.2 158.3
CH
Novartis AG
SIX:NOVN
206B CHF 4.6 17.7 11.3 14.5
US
Merck & Co Inc
NYSE:MRK
239.1B USD 3.7 12.6 9 10.7
DK
Novo Nordisk A/S
CSE:NOVO B
1.3T DKK 4.2 12.8 8.9 10.4
IE
Endo International PLC
LSE:0Y5F
202.5B USD 87.3 -69.3 321.2 805.4
US
Pfizer Inc
NYSE:PFE
145.2B USD 2.3 14.8 7.5 10.3
P/E Multiple
Earnings Growth PEG
US
Supernus Pharmaceuticals Inc
NASDAQ:SUPN
Average P/E: 23.1
Negative Multiple: -140
55%
N/A
US
Eli Lilly and Co
NYSE:LLY
51
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.3
29%
0.7
CH
Roche Holding AG
SIX:ROG
26.8
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
29.9
38%
0.8
CH
Novartis AG
SIX:NOVN
17.7
17%
1
US
Merck & Co Inc
NYSE:MRK
12.6
15%
0.8
DK
Novo Nordisk A/S
CSE:NOVO B
12.8
4%
3.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -69.3 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.8
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Supernus Pharmaceuticals Inc
NASDAQ:SUPN
Average EV/EBITDA: 399.4
18.9
24%
0.8
US
Eli Lilly and Co
NYSE:LLY
34.3
33%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
15.8
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.5
4%
2.9
UK
AstraZeneca PLC
LSE:AZN
108.2
10%
10.8
CH
Novartis AG
SIX:NOVN
11.3
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9
6%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
8.9
2%
4.5
IE
E
Endo International PLC
LSE:0Y5F
321.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
1%
7.5
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Supernus Pharmaceuticals Inc
NASDAQ:SUPN
Average EV/EBIT: 1 712.8
57.9
53%
1.1
US
Eli Lilly and Co
NYSE:LLY
36.8
36%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.5
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.4
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
158.3
23%
6.9
CH
Novartis AG
SIX:NOVN
14.5
12%
1.2
US
Merck & Co Inc
NYSE:MRK
10.7
8%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
10.4
1%
10.4
IE
E
Endo International PLC
LSE:0Y5F
805.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
8%
1.3